Drug Target Review

JULY 1, 2025

Unlearn’s digital twins are now in use in both early and late-stage clinical trials, with adoption continuing to grow. Solving old problems in new ways Herne is well acquainted with the operational inefficiencies that persist across clinical development.

Clinical Trials

PPD

JUNE 20, 2025

Prioritizing the idiopathic pulmonary fibrosis patient experience in clinical trials Understanding the patient experience is paramount to the success of idiopathic pulmonary fibrosis clinical development. Even attending their regular clinic visits can be exhausting and stressful. Ready to connect?

Clinical Development

Drug Target Review

JULY 24, 2025

Meet Jhong-Jhe (JJ) You JJ joined AP Biosciences in 2013 as the company’s first employee, leading the development of the Omni-Mab human antibody phage display library and building a robust cell-based assay platform for screening and isolating functional antibodies for immunotherapy.

Immune Response

The Pharma Data

JUNE 12, 2025

We look forward to further evaluating rilzabrutinib in subsequent phases of its clinical development.” Food and Drug Administration (FDA) recognized the significance of rilzabrutinib’s potential by granting Fast Track designation in May 2025 and Orphan Drug designation in April 2025 for its development in IgG4-related disease.

Disease

The Pharma Data

JUNE 25, 2025

By integrating Regulus’ expertise in microRNA science with its own deep capabilities in clinical development, regulatory affairs, and commercialization, Novartis is well-positioned to accelerate farabursen’s clinical path and potentially bring a first-in-class treatment to ADPKD patients.

RNA

Drug Target Review

JUNE 6, 2025

End-to-end development Unlike many organisations in the pharmaceutical sector, RadioMedix maintains an integrated model from pre-clinical development through to commercial manufacturing. This philosophy guides RMX’s collaborative efforts, whether the partner is focused on discovery, clinical development or commercialisation. “We

Therapies

The Pharma Data

JUNE 16, 2025

Our respective expertise — their extensive experience in clinical development and navigating the Chinese market , alongside our own strength in biologic innovation and growing pipeline of novel oncology treatments — forms a powerful synergy.

Therapies

Drug Target Review

APRIL 30, 2025

Her work has enabled the production of critical cGMP-compliant materials, accelerating clinical development and commercialisation. She has also championed workforce development, creating education programmes from school level to higher education to build a skilled talent pipeline.

Drugs

The Pharma Data

JUNE 18, 2025

“As our science has advanced, so has the need for tighter alignment across Research and Development to ensure that we continue to scale our impact and transform the lives of patients across a growing number of diseases,” Greenstreet stated. A New Chapter for Alnylam and RNAi Science With Dr.

RNA

Drug Target Review

FEBRUARY 10, 2025

Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies. My focus has always been on advancing novel medicines from research to clinical development. Over the years, Ive had the privilege of working on more than 25 different products, Bock shared.

Therapies

Drug Target Review

JUNE 28, 2025

.” Beyond that, the second MSLN Radio-DARPin is advancing and Switch-DARPin development is progressing further. “We will communicate specific next steps, including clinical development plans… in due time,” says Croset.

Science

The Pharma Data

JUNE 22, 2025

Broader Clinical Program and Regulatory Pathway Mim8, a next-generation investigational bispecific antibody, is currently being evaluated across multiple studies within Novo Nordisk’s comprehensive FRONTIER clinical development program.

Pharmacokinetics

The Pharma Data

JUNE 13, 2025

Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. “As formerly Cellular Biomedicine Group, Inc.).

Therapies

Drug Target Review

JULY 18, 2025

DT-7012 retains its depletion activity even in high CCL1-concentrated environments – an essential property not shared by most competitor antibodies currently in clinical development.” Preparing for the clinic Preclinical success is just the beginning. For DT-7012, Domain is now translating its data into clinical plans.

Medical Chemistry

The Pharma Data

JUNE 22, 2025

The results from the Phase I/II NXTAGE trial, announced during the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.,

Clinical Trials

The Pharma Data

JUNE 18, 2025

Dr. Marjorie Green, Senior Vice President and Head of Oncology Global Clinical Development at Merck Research Laboratories, emphasized the significance of this new trial within the broader scope of the ADC’s development.

Trials

The Pharma Data

JUNE 24, 2025

In contrast to a conventional pharma partnership, this large scale and flexible funding agreement enables Revolution Medicines to retain control of the clinical development of daraxonrasib, as well as the ability to capture significant value creation that would result from the successful clinical development and commercialization of its pipeline.”

Drug Development

Alta Sciences

FEBRUARY 19, 2025

Regulatory Considerations for Oligonucleotide Drug Development and Safety In 2024, the U.S. It also outlines recommendations for drug-drug interaction assessments during clinical development, such as the assessment of appropriate biomarkers that reflect modulation of the target protein.

Drug Development

The Pharma Data

JUNE 12, 2025

Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine.

Treatment

Drug Target Review

JUNE 11, 2025

Using clinical genomics and AI in drug development to elevate success. Early evidence and emerging trends: How AI is shaping drug discovery and clinical development. The Rise of Multimodal Language Models in Drug Development (2025). EPR Pharma Horizons Report: The impact of Artificial Intelligence.

Drugs

The Pharma Data

JUNE 23, 2025

This study explored the effects of beginning treatment with lower starting doses of MariTide to improve tolerability while maintaining clinical benefit. Both data sets now provide foundational insight into the design and direction of Amgen’s upcoming Phase 3 MARITIME clinical development program.

Trials

SugarCone Biotech

JUNE 19, 2025

Amgen’s clinical development studies of tarlatamab include the DeLLphi-305 trial in ES-SCLC testing a first-line maintenance regimen following durvalumab plus chemo (Amgen markets the anti-PD-L1 checkpoint inhibitor durvalumab). The tarlatamab results have of course triggered a stampede of development of DLL3-targeted therapies.

Therapies

PPD

NOVEMBER 11, 2024

Companies can benefit from solutions such as our Accelerator Drug Development, leveraging the combined strength of Thermo Fisher Scientific’s 360˚ Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services , which provides CDMO, CRO and clinical trial supply chain capabilities that further streamline (..)

Drug Development

Drug Target Review

MAY 23, 2025

When asked about POLB 001s safety profile, he said, Clinical development is an incremental process. We investigate every potential signal and at every stage of development. We have a focus on the overall risk-benefit profile of a drug.

Immune Response

PPD

JANUARY 15, 2025

About us The PPD clinical research business of Thermo Fisher Scientific , the world leader in serving science, enables our customers to accelerate innovation and increase drug development productivity. Ready to learn more about how to leverage AI and machine learning to maximize your clinical trial efficiency?

Clinical Trials

thought leadership

FEBRUARY 26, 2025

Rare diseases are defined in the Orphan Drug Act as diseases or conditions that affect less than 200,000 people in the United States.

Clinical Development

DrugBank

JUNE 18, 2025

Before a drug can enter human trials, researchers must submit an IND to regulatory agencies, providing preclinical toxicology data, proposed clinical trial designs, and manufacturing details. This application is the foundation for obtaining approval to proceed with Phase I human trials.

Drug Development

The Pharma Data

JUNE 24, 2025

This significant financial infusion is designed to fuel Revolution Medicines’ ambitious clinical development and commercialization plans, with a particular focus on its groundbreaking RAS(ON) inhibitor programs for patients with RAS-addicted cancers.

Clinical Development

PPD

MARCH 11, 2025

Real-world data (RWD) and real-world evidence (RWE) have emerged as transformational tools in addressing these hurdles, advancing rare disease drug development.

Drug Development

PPD

JUNE 17, 2025

These hubs support a geographically distributed remote workforce that provides greater stability and project continuity while offering the global expertise and capabilities needed to bolster clinical development success.

Clinical Development

The Pharma Data

JUNE 15, 2025

Clinical Development Plans and Future Outlook Intellia’s ongoing Phase 3, randomized, double-blind, placebo-controlled HAELO trial is currently assessing the safety and efficacy of lonvo-z at the 50 mg dose in a larger patient population.

Treatment

The Pharma Data

JUNE 22, 2025

Building on the STELLAR Clinical Program The STELLAR-303 trial is part of a broader clinical development strategy for zanzalintinib, which Exelixis is evaluating in multiple tumor types. “We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.”

Trials

The Pharma Data

JUNE 11, 2025

With eight wholly owned neurology programs currently in clinical development, Ionis continues to expand its pipeline targeting a diverse array of rare and more prevalent neurological disorders. The REVEAL trial represents a critical step forward not only for ION582 but also for the broader field of precision neurology.

Trials

The Pharma Data

JUNE 26, 2025

This unmet need has driven the development of alternative pharmacological options, including topical eye drops like MR-141, which aim to improve near vision through non-surgical means. Details of the VEGA-3 Phase 3 Trial The VEGA-3 study is part of Viatris’ broader clinical development program to evaluate MR-141 for presbyopia.

Trials

The Pharma Data

JUNE 12, 2025

The initial data presented at EHA show a manageable safety profile alongside signals of clinical activity, offering hope for patients with limited treatment options in relapsed or refractory NHL.

Targeted Protein Degradation

Alta Sciences

JULY 7, 2025

The focus is to ensure that the drug does not have any potential to induce an excessive immune response, particularly cytokine storm, which can lead to severe adverse effects and impede clinical development.

Immune Response

The Pharma Data

JUNE 25, 2025

The development of targeted therapies like riliprubart represents a paradigm shift , aiming to improve not just graft survival, but overall patient quality of life.

FDA